Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant acinetobacter baumannii in a murine thigh-infection model

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Fan, Bing ^a,b   Guan, Jie ^c   Wang, Xiumei ^b   Cong, Yulong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; FOSFOMYCIN; FUSIDIC ACID; MEROPENEM; RIFAMPICIN; SULBACTAM; TIGECYCLINE; DRUG COMBINATION; MINOCYCLINE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOUSE; MYOSITIS; NONHUMAN; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; THIGH; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; COLISTIN; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; FOSFOMYCIN; FUSIDIC ACID; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; SULBACTAM; THIENAMYCINS;

EID: 84976354772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157757     Document Type: Article

References (39)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51:3471-3484. doi: 10.1128/ AAC.01464-06 PMID: 17646423
2. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008; 46:1254-1263. doi: 10.1086/529198 PMID: 18444865
3. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18:268-281. doi: 10.1111/j. 1469-0691.2011.03570.x PMID: 21793988
4. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis. 2011; 52:352e60. doi: 10.1093/cid/ciq154 PMID: 21193494
5. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012; 10:917-934. doi: 10.1586/eri.12.78 PMID: 23030331
6. Vila J, Pachón J. Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opin Pharmacother. 2012; 13:2319-2336. doi: 10.1517/14656566.2012.729820 PMID: 23035697
7. Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother. 2013; 57:3738-3745. doi: 10.1128/ AAC.00703-13 PMID: 23716052
8. Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents. 2015; 45:8-18.
9. doi: 10.1016/j.ijantimicag.2014.10.002 PMID: 25465524
10. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014; 69:2305-2309. doi: 10.1093/jac/dku168 PMID: 24872346
11. Gouby A, Carles-Nurit MJ, Bouziges N, Bourg G, Mesnard R, Bouvet PJ. Use of pulsed-field gel electrophoresis for investigation of hospital outbreaks of Acinetobacter baumannii. J Clin Microbiol. 1992; 30:1588-1591. PMID: 1352519
12. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33:2233-2239. PMID: 7494007
13. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2007; 60:317-22. PMID: 17540672
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational Supplement. CLSI document M100-S24 / Wayne, PA: CLSI, 2014.
15. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- ninth edition. CLSI document M07-A9 / Wayne, PA: CLSI, 2012.
16. Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, et al. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2013; 57:6028-6033. doi: 10. 1128/AAC.00891-13 PMID: 24060874
17. Pachón-Ibáñez ME, Docobo-Pxrez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010; 54:1165-1172. doi: 10.1128/AAC.00367-09 PMID: 20047914
18. Morinaga Y, Yanagihara K, Nakamura S, Yamamoto K, Izumikawa K, Seki M, et al. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother. 2008; 62:1326-1331. doi: 10.1093/jac/dkn411 PMID: 18835805
19. Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ. Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother. 2010; 54:643-651. doi: 10.1128/AAC.00788-09 PMID: 19995919
20. Lefort A, Chau F, Lepeule R, Dubée V, Kitzis MD, Dion S, et al. Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase. Int J Antimicrob Agents. 2014; 43:366-369.
21. doi: 10.1016/j.ijantimicag.2013.12.001 PMID: 24388117
22. Bellahsène A, Forsgren A. Effect of fusidic acid on the immune response in mice. Infect Immun. 1980; 29:873-878. PMID: 6448821
23. Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, et al. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis. Chemotherapy. 2013; 59:325-329. doi: 10.1159/000356755 PMID: 24525528
24. Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med. 2015; 43:1194-1204. doi: 10.1097/CCM.0000000000000933 PMID: 25793437
25. Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, et al. Efficacy of colistin versus betalactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2002; 46:1946-1952. PMID: 12019113
26. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, et al. Systematic review and metaanalysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013; 57:5104-5111. doi: 10.1128/AAC.01230-13 PMID: 23917322
27. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents. 2009; 33:33-39. doi: 10.1016/j.ijantimicag.2008.07.008 PMID: 18835761
28. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drugresistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013; 57:349-358. doi: 10.1093/cid/cit253 PMID: 23616495
29. Pogue JM, Kaye KS. Is there really no benefit to combination therapy with colistin? Expert Rev Anti Infect Ther. 2013; 11:881-884. doi: 10.1586/14787210.2013.827881 PMID: 24053270
30. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycincolistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010; 54:5316-5322. doi: 10.1128/AAC.00922-10 PMID: 20876375
31. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother. 2011; 66:1047-1051.
32. doi: 10.1093/jac/dkr069 PMID: 21393131
33. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2014; 43:370-374. doi: 10.1016/j.ijantimicag.2013.12.010 PMID: 24560919
34. Phee LM, Betts JW, Bharathan B, Wareham DW. Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2015; 59:4544-4550. doi: 10.1128/AAC.00753-15 PMID: 25987639
35. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev. 1992; 56:395-411. PMID: 1406489
36. Hornsey M, Wareham DW. In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2011; 55:3534-3537. doi: 10.1128/AAC.00230-11 PMID: 21502628
37. Hornsey M, Phee L, Longshaw C, Wareham DW. In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2013; 41:285-287. doi: 10.1016/j.ijantimicag.2012.11.013 PMID: 23312607
38. Yang H, Chen G, Hu L, Liu Y, Cheng J, Li H, et al. In vivo activity of daptomycin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents. 2015; 45:188-191. doi: 10.1016/j.ijantimicag.2014.10.012 PMID: 25440154
39. Mutlu Yilmaz E, Sunbul M, Aksoy A, Yilmaz H, Guney AK, Guvenc T. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012; 40:332-336. doi: 10.1016/j.ijantimicag.2012.06.003 PMID: 22831842